Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 7/20 | 0.59 |
| ▸ | CASP1 | P29466 | 14/20 | 0.55 |
| ▸ | CASP7 | P55210 | 5/20 | 0.54 |
| ▸ | CASP9 | P55211 | 2/20 | 0.54 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.52 |
| ▸ | CASP4 | P49662 | 2/20 | 0.51 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27544008 | 1.00 | CASP3 (0.59) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL7472606 | 0.96 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL7197707 | 0.89 | CASP3 (0.50) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL4466395 | 0.89 | CASP3 (0.60) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL29384302 | 0.89 | CASP3 (0.60) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL26071633 | 0.89 | CASP3 (0.60) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL19067195 | 0.89 | CASP1 (0.57) | CASP1 | |
| SCHEMBL4420464 | 0.89 | CASP3 (0.67) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL7383742 | 0.89 | CASP3 (0.67) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL10074125 | 0.88 | CASP3 (0.49) | CASP3CASP1CASP7CASP9CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1313846-A | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases | IDUN PHARMACEUTICALS INC (US) | 2001-09-19 | — | — | CN | disclosed |